<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04774393</url>
  </required_header>
  <id_info>
    <org_study_id>2020-1220</org_study_id>
    <secondary_id>NCI-2021-00893</secondary_id>
    <secondary_id>2020-1220</secondary_id>
    <nct_id>NCT04774393</nct_id>
  </id_info>
  <brief_title>Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia</brief_title>
  <official_title>Phase 1b/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase Ib/II trials studies the side effects of decitabine/cedazuridine (ASTX727) and&#xD;
      venetoclax in combination with ivosidenib or enasidenib, and how well they work in treating&#xD;
      patients with acute myeloid leukemia that has come back (relapsed) or does not respond to&#xD;
      treatment (refractory). ASTX727 is the combination of a fixed dose of 2 drugs, cedazuridine&#xD;
      and decitabine. Cedazuridine may slow down how fast decitabine is broken down by the body,&#xD;
      and decitabine may block abnormal cells or cancer cells from growing. Venetoclax may stop the&#xD;
      growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival.&#xD;
      Enasidenib and ivosidenib may stop the growth of cancer cells by blocking some of the enzymes&#xD;
      needed for cell growth. Giving decitabine/cedazuridine and venetoclax in combination with&#xD;
      ivosidenib or enasidenib may help control acute myeloid leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To determine the safety and tolerability and recommended phase 2 dose (RP2D) of oral&#xD;
      decitabine/cedazuridine (ASTX727) and venetoclax in combination with either ivosidenib (Arm&#xD;
      A) or enasidenib (Arm B) for patients with acute myeloid leukemia. (Phase Ib) II. To&#xD;
      determine the overall response rate (complete response [CR], complete remission with&#xD;
      incomplete hematologic recovery [CRh], morphologic leukemia-free state [MLFS] and partial&#xD;
      response [PR)] of oral decitabine/cedazuridine (ASTX727) and venetoclax in combination with&#xD;
      either ivosidenib (Arm A) or enasidenib (Arm B) for patients with acute myeloid leukemia.&#xD;
      (Phase 2)&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine duration of response (DOR), event-free survival (EFS), and overall survival&#xD;
      (OS).&#xD;
&#xD;
      II. To evaluate occurrence of minimal residual disease (MRD) negative status by&#xD;
      multiparameter flow cytometry and molecular evaluation.&#xD;
&#xD;
      EXPLORATORY OBJECTIVE:&#xD;
&#xD;
      I. To investigate global gene expression profiles, deoxyribonucleic acid (DNA) methylation&#xD;
      profiles, BH3 profiling and other potential prognostic markers to explore predictors of&#xD;
      antitumor activity and/or resistance to treatment.&#xD;
&#xD;
      OUTLINE: Patients are assigned to 1 of 2 arms.&#xD;
&#xD;
      ARM A: Patients receive decitabine/cedazuridine orally (PO) daily on days 1-5, venetoclax PO&#xD;
      daily on days 1-14, and ivosidenib PO daily on days 1-28. Treatment repeats every 28 days for&#xD;
      12 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      ARM B: Patients receive decitabine/cedazuridine PO daily on days 1-5, venetoclax PO daily on&#xD;
      days 1-14, and enasidenib PO daily on days 1-28. Treatment repeats every 28 days for 12&#xD;
      cycles in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 24, 2021</start_date>
  <completion_date type="Anticipated">November 29, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 29, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity (Phase Ib)</measure>
    <time_frame>Up to 1 cycle (1 cycle = 28 days)</time_frame>
    <description>Will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5 by organ system.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate (ORR) (Phase II)</measure>
    <time_frame>Within 4 months of treatment</time_frame>
    <description>Defined as complete remission (CR), CR with incomplete hematologic recovery, CR with incomplete count recovery, partial response or marrow clearance of blasts. Will estimate the ORR for the combination treatmen1t, along with the Bayesian 95% credible interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events (Phase II)</measure>
    <time_frame>Within 4 months of treatment</time_frame>
    <description>Assessed using Common Toxicity Criteria version 5.0. Safety data will be summarized using frequency and percentage, by category and severity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>Time interval between treatment start until disease progression, relapse/refractory, or death due to any cause, assessed up to 3 years</time_frame>
    <description>The Kaplan-Meier method will be used to estimate the probabilities of EFS. Log-rank tests will be used to compare among subgroups of patients in terms of EFS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Time interval between treatment start until death due to any cause, assessed up to 3 years</time_frame>
    <description>The Kaplan-Meier method will be used to estimate the probabilities of OS. Log-rank tests will be used to compare among subgroups of patients in terms of OS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The Kaplan-Meier method will be used to estimate the probabilities and log-rank tests will be used to compare among subgroups of patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal residual disease negative status</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will be summarized graphically and with descriptive statistics. The association between molecular and cellular markers and overall response and/or resistance will be assessed through logistic regression analyses. Paired t-test or Wilcoxon signed rank test will be used to assess the marker change over time.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Recurrent Acute Myeloid Leukemia</condition>
  <condition>Refractory Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm A (decitabine/cedazuridine, venetoclax, ivosidenib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive decitabine/cedazuridine PO daily on days 1-5, venetoclax PO daily on days 1-14, and ivosidenib PO daily on days 1-28. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (decitabine/cedazuridine, venetoclax, enasidenib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive decitabine/cedazuridine PO daily on days 1-5, venetoclax PO daily on days 1-14, and enasidenib PO daily on days 1-28. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine and Cedazuridine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm A (decitabine/cedazuridine, venetoclax, ivosidenib)</arm_group_label>
    <arm_group_label>Arm B (decitabine/cedazuridine, venetoclax, enasidenib)</arm_group_label>
    <other_name>ASTX727</other_name>
    <other_name>CDA Inhibitor E7727/Decitabine Combination Agent ASTX727</other_name>
    <other_name>Cedazuridine/Decitabine Combination Agent ASTX727</other_name>
    <other_name>Cedazuridine/Decitabine Tablet</other_name>
    <other_name>Inqovi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enasidenib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm B (decitabine/cedazuridine, venetoclax, enasidenib)</arm_group_label>
    <other_name>AG-221</other_name>
    <other_name>CC-90007 Free Base</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivosidenib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm A (decitabine/cedazuridine, venetoclax, ivosidenib)</arm_group_label>
    <other_name>AG-120</other_name>
    <other_name>Tibsovo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm A (decitabine/cedazuridine, venetoclax, ivosidenib)</arm_group_label>
    <arm_group_label>Arm B (decitabine/cedazuridine, venetoclax, enasidenib)</arm_group_label>
    <other_name>ABT-0199</other_name>
    <other_name>ABT-199</other_name>
    <other_name>ABT199</other_name>
    <other_name>GDC-0199</other_name>
    <other_name>RG7601</other_name>
    <other_name>Venclexta</other_name>
    <other_name>Venclyxto</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a diagnosis of relapsed or refractory acute myeloid leukemia (AML)&#xD;
             (including biphenotypic or bilineage leukemia including a myeloid component or&#xD;
             isolated extramedullary AML); OR&#xD;
&#xD;
          -  Patients (&gt; 60 year old) with newly diagnosed AML not eligible for intensive&#xD;
             chemotherapy are also eligible&#xD;
&#xD;
          -  Age &gt;= 18 years&#xD;
&#xD;
          -  Subjects must have documented IDH1 or IDH2 gene mutation&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2&#xD;
&#xD;
          -  Adequate renal function including creatinine &lt; 2 unless related to the disease&#xD;
&#xD;
          -  Direct bilirubin &lt; 2 x upper limit of normal (ULN) unless increase is due to Gilbert's&#xD;
             disease or leukemic involvement&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) &lt; 3 x ULN&#xD;
             unless considered due to leukemic involvement, in which case direct bilirubin or AST&#xD;
             and/or ALT &lt; 5 x ULN will be considered eligible)&#xD;
&#xD;
          -  In the absence of rapidly proliferative disease, the interval from prior treatment to&#xD;
             time of initiation will be at least 7 days for cytotoxic or non-cytotoxic&#xD;
             (immunotherapy agent(s). Oral hydroxyurea and/or cytarabine (up to 2 g/m^2) for&#xD;
             patients with rapidly proliferative disease is allowed before the start of study&#xD;
             therapy, as needed, for clinical benefit and after discussion with the principle&#xD;
             investigator (PI). Concurrent therapy for central nervous system (CNS) prophylaxis or&#xD;
             continuation of therapy for controlled CNS disease is permitted&#xD;
&#xD;
          -  Male subjects who are sexually active with a women of childbearing potential (WOCBP)&#xD;
             and who have not had vasectomies must be willing to use a barrier method of&#xD;
             contraception and refrain from sperm donation from initial study drug until 90 days&#xD;
             after last dose of study drug&#xD;
&#xD;
          -  Willing and able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with t(15;17) karyotypic abnormality or acute promyelocytic leukemia&#xD;
             (French-American-British [FAB] class M3-AML)&#xD;
&#xD;
          -  Patients with any concurrent uncontrolled clinically significant medical condition&#xD;
             including life-threatening severe infection, or psychiatric illness, which could place&#xD;
             the patient at unacceptable risk of study treatment&#xD;
&#xD;
          -  Patients with active graft-versus-host-disease (GVHD) status post stem cell transplant&#xD;
             (patients without active GVHD on chronic suppressive immunosuppression and/or&#xD;
             phototherapy for chronic skin GVHD are permitted after discussion with the PI)&#xD;
&#xD;
          -  Patients with any severe gastrointestinal or metabolic condition which could interfere&#xD;
             with the absorption of oral study medications&#xD;
&#xD;
          -  Corrected QT (QTc) interval using Fridericia's formula (QTcF) &gt;= 450 msec. Bundle&#xD;
             branch block and prolonged QTc interval are permitted after discussion with the PI&#xD;
&#xD;
          -  Known active hepatitis B (HBV) or hepatitis C (HCV) infection or known human&#xD;
             immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Subject has a white blood cell count &gt; 25 x 10^9/L. (Note: Hydroxyurea is permitted to&#xD;
             meet this criterion)&#xD;
&#xD;
          -  Nursing women, women of childbearing potential (WOCBP) with positive urine pregnancy&#xD;
             test, or women of childbearing potential who are not willing to maintain adequate&#xD;
             contraception&#xD;
&#xD;
               -  Appropriate highly effective method(s) of contraception include oral or&#xD;
                  injectable hormonal birth control, intrauterine device (IUD), and double barrier&#xD;
                  methods (for example a condom in combination with a spermicide)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Courtney DiNardo</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney DiNardo</last_name>
      <phone>713-794-1141</phone>
      <email>cdinardo@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Courtney DiNardo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 24, 2021</study_first_submitted>
  <study_first_submitted_qc>February 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
    <mesh_term>Ivosidenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

